spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Element Materials Unveils One of the First and Largest Air Treatment Testing Facilities Designed to Support Indoor Space Public Health Air Quality

Element Materials Technology

7,500ft3 Facility Now Open to Evaluate Aerosolized Product Efficacy; Reduce Airborne Organisms, Viral Particles



EAGAN, MN, USA and LONDON, UK – November 16, 2022 – Element Materials Technology (Element), a leading global Testing, Inspection and Certification (TIC) company, today unveiled one of the first and largest post-pandemic, commercial bioaerosol testing facilities. It is designed to evaluate the efficacy of aerosolized products to reduce or eliminate indoor airborne organisms and viral particles in habitable spaces such as transportation, hospitals, and schools. The state-of-the-art lab is at the company’s Eagan, Minnesota site.



“The need for bioaerosols was defined by the pandemic, and Element is pleased to bring the industry this new, much-needed capability to fulfill emerging and critical testing needs. Precise and accurate air quality testing will be critical for public health for the future,” said Dr. Elisabeth Lackner, CSO of Element. “The capability of the new Eagan lab is a shining example of how Element teams with customers to meet their evolving market demands. We are helping customers to establish purposefully designed bioaerosol R&D level protocols that provide a strong foundation for future GLP-compliant testing.”

Element has industry-leading experience with antimicrobial testing of fogging and misting devices, and now without size constraints, the Eagan lab offers real-world modeling of habitable spaces such as hospitals, schools, and other large spaces. Element’s applied microbiologists teamed with industry experts to design its 7,500-cubic foot biocontainment lab that can be used in a dual or single capacity allowing for simultaneous testing of control and treated space under the same conditions. Various size configurations of, but not limited to, 107m3 and 214m3 can be accommodated. In addition to managing multiple air handling scenarios, including the introduction of fresh or recirculated air, the facility has the unique capacity to test BSL-2 organisms including mammalian viruses.

“Previously designed for a specific testing project, today marks the formal opening of this unique facility,” said Kelly Lauer, General Manager, Element Eagan. “Element has proudly provided antimicrobial testing services and support in partnership with the developers, manufacturers, and users of antimicrobial pesticide and biocide products for more than 30 years. With the addition of this leading-edge bioaerosol testing facility in Eagan, Element continues its history of innovation.”

The U.S. Environmental Protection Agency (EPA) aims to release guidance for air treatments in 2022 or early 2023, and Element has played an instrumental role in developing a standard test method for EPA-approved public health claims for air treatments, collaborating with regulatory, academic, and industry experts.

Element’s global life sciences division includes more than 1,400 scientists, chemists, and technologists working across a network of laboratories to deliver complete and comprehensive scientific solutions that support customers’ end-to-end product development lifecycle from early R&D through complex regulatory approvals, into production and beyond.

Companies interested in more information on testing can contact the lab directly at Bioaerosol.Info@Element.com.
phone +49 (0)40 8740 8163
web https://www.element.com/
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern Europe

Brussels, 30 November 2022 – Myeloma Patients Europe (MPE) has launched a first-of-its-kind advocacy report on Addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE)
More info >>


White Papers

Conveying Medical Guidance in Clinical Trials – A Survey

Europital Medical Consultancy

With the incremental demand for proactive safety surveillance throughout the conduct of clinical trials, the role of Medical Management is at the fore in ensuring the safety and wellbeing of the participants. The complex responsibilities of a Medical Monitor (MM) starts from the design and development phase, through to study close out. Understanding the principle behind the protocol and the prospective medical solution the study would deliver forms the bloodline for the MM role. Often, the MM is the face of contact for both the site personnel and the study team members with regard to medical, safety and scientific issues within the project. When it comes to medical guidance, the communication channel used to deliver solutions contributes to a large extent in effectively managing decisive situations. Our previous study on acquiring medical guidance from an operations team perspective revealed that e-mails were the most used communication method (see the article, 'Talking Points', in ICT November 2014). In our efforts to further strengthen the mode of medical guidance delivery, we designed a survey to study the existing trend and constraints in this communication chain management, as outlined here.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement